These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 9279289)

  • 1. Danaparoid: an antithrombotic agent without major impact on triglyceride hydrolysis capacity in humans.
    van Barlingen HH; van Beek A; Erkelens DW; de Bruin TW
    J Intern Med; 1997 Aug; 242(2):125-9. PubMed ID: 9279289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Danaparoid: an anti-thrombotic agent without major impact on triglyceride hydrolysis capacity in humans.
    Mikhailidis DP; Jagroop IA
    J Intern Med; 1998 Aug; 244(2):184. PubMed ID: 10095808
    [No Abstract]   [Full Text] [Related]  

  • 3. Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia.
    Wilde MI; Markham A
    Drugs; 1997 Dec; 54(6):903-24. PubMed ID: 9421696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Thrombocytopenia due to heparin therapy. Use of danaparoid (Orgaran), 13 monocentric cases under authorization of temporary prescription (ATU)].
    Gindre L; de Maistre E; Perrin A; Lecompte T; Hoffman MA
    Therapie; 1997; 52(6):591-7. PubMed ID: 9734113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of danaparoid during continuous venovenous hemofiltration: a pilot study.
    de Pont AC; Hofstra JJ; Pik DR; Meijers JC; Schultz MJ
    Crit Care; 2007; 11(5):R102. PubMed ID: 17854496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of unfractionated heparin, low-molecular-weight heparin, and heparinoid on thromboelastographic assay of blood coagulation.
    Zmuda K; Neofotistos D; Ts'ao CH
    Am J Clin Pathol; 2000 May; 113(5):725-31. PubMed ID: 10800406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Danaparoid in the prevention of thromboembolic complications.
    Skoutakis VA
    Ann Pharmacother; 1997; 31(7-8):876-87. PubMed ID: 9220051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraoperative monitoring of danaparoid sodium anticoagulation during cardiovascular operations.
    Gitlin SD; Deeb GM; Yann C; Schmaier AH
    J Vasc Surg; 1998 Mar; 27(3):568-75. PubMed ID: 9546248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-affinity material does not contribute to the antithrombotic activity of Orgaran (Org 10172) in human plasma.
    Zammit A; Dawes J
    Thromb Haemost; 1994 Jun; 71(6):759-67. PubMed ID: 7526481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Heparin-associated platelet aggregation syndrome with skin necrosis during hemodialysis].
    Bredlich RO; Stracke S; Gall H; Proebstle TM
    Dtsch Med Wochenschr; 1997 Mar; 122(11):328-32. PubMed ID: 9102281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Danaparoid sodium for dialysis in heparin-associated thrombocytopenia].
    Ben Ami R; Rachmimov R; Berliner S
    Harefuah; 1999 Mar; 136(5):361-4, 419. PubMed ID: 10914239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical cross-reactivity between danaparoid and heparin antibodies successfully managed with bivalirudin.
    Shapiro M; Cohen J; Inbal A; Singer P
    Isr Med Assoc J; 2009 Mar; 11(3):188-90. PubMed ID: 19544713
    [No Abstract]   [Full Text] [Related]  

  • 13. A comparison of the effects of unfractionated heparin, dalteparin and danaparoid on vascular endothelial growth factor-induced tumour angiogenesis and heparanase activity.
    Takahashi H; Ebihara S; Okazaki T; Asada M; Sasaki H; Yamaya M
    Br J Pharmacol; 2005 Oct; 146(3):333-43. PubMed ID: 16041398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of danaparoid, dalteparin and heparin on tissue factor-induced experimental disseminated intravascular coagulation and bleeding time in the rat.
    Miyake Y; Yokota K; Fujishima Y; Sukamoto T
    Blood Coagul Fibrinolysis; 2001 Jul; 12(5):349-57. PubMed ID: 11505077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The platelet proaggregating and potentiating effects of unfractionated heparin, low molecular weight heparin and heparinoid in intensive care patients and healthy controls.
    Burgess JK; Chong BH
    Eur J Haematol; 1997 Apr; 58(4):279-85. PubMed ID: 9186540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Standard heparin, low molecular weight heparin, low molecular weight heparinoid, and recombinant hirudin differ in their ability to inhibit transduction by recombinant adeno-associated virus type 2 vectors.
    Hacker UT; Gerner FM; Büning H; Hutter M; Reichenspurner H; Stangl M; Hallek M
    Gene Ther; 2001 Jun; 8(12):966-8. PubMed ID: 11426338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased sulphation improves the anticoagulant activities of heparan sulphate and dermatan sulphate.
    Ofosu FA; Modi GJ; Blajchman MA; Buchanan MR; Johnson EA
    Biochem J; 1987 Dec; 248(3):889-96. PubMed ID: 2963622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticoagulation with recombinant hirudin and danaparoid sodium in pediatric patients.
    Severin T; Zieger B; Sutor AH
    Semin Thromb Hemost; 2002 Oct; 28(5):447-54. PubMed ID: 12420240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial.
    de Valk HW; Banga JD; Wester JW; Brouwer CB; van Hessen MW; Meuwissen OJ; Hart HC; Sixma JJ; Nieuwenhuis HK
    Ann Intern Med; 1995 Jul; 123(1):1-9. PubMed ID: 7539233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of danaparoid sodium, dalteparin sodium and heparin determined by inhibitory effect on the activated coagulation factor X activity after single intravenous administration in rabbits.
    Ishida M; Nakada Y; Horiuchi M; Sakamoto F
    Arzneimittelforschung; 1998 Aug; 48(8):818-21. PubMed ID: 9748709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.